Showing results (251-260 of 438) with videos related to
Sort By:
Pageof 44
Journal of Stem Cell Research & Therapy|October 3, 2017
Referral Patterns and Clinical Outcomes for Transplant-Eligible Lymphoma and Myeloma Patients Evaluated at an Urban County HospitalHyun D Yun, Tehseen Dossul, Leon Bernal-Mizrachi, et al.Southern Medical Journal|August 2, 2014
Incidence and geographic distribution of adult acute leukemia in the state of GeorgiaFuad El Rassi, Kevin C Ward, Christopher R Flowers, et al.Transfusion|April 16, 2011
Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kineticsJie Li, Ellie Hamilton, Louette Vaughn, et al.Clinical Lymphoma, Myeloma & Leukemia|October 8, 2013
Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphomaRajni Sinha, Pareen J Shenoy, Nassoma King, et al.Cancer|April 16, 2026
Assessing patient perspectives on enrollment in lymphoma clinical trialsNeha Akkad, Minxing Chen, Sophia Nguyen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2015
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare StudyCarla Casulo, Michelle Byrtek, Keith L Dawson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2017
American Society of Clinical Oncology Strategic Plan for Increasing Racial and Ethnic Diversity in the Oncology WorkforceKaren M Winkfield, Christopher R Flowers, Jyoti D Patel, et al.BMC Cancer|March 18, 2017
Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United StatesChadi Nabhan, Anthony Mato, Christopher R Flowers, et al.Cells|July 29, 2023
Adjunct Therapy with T Regulatory Cells Decreases Inflammation and Preserves the Anti-Tumor Activity of CAR T CellsKe Zeng, Meixian Huang, Mi-Ae Lyu, et al.Cancer|April 27, 2012
A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomasRajni Sinha, Jonathan L Kaufman, Hanna Jean Khoury, et al.Pageof 44